14-day Premium Trial Subscription Try For FreeTry Free

Cabaletta Bio, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 80.43. In total, the insiders bought 4 987 184 and sold 1 588 470 CABA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
80.43
Buy 4 987 184 Shares
Sell 1 588 470 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 03, 2024 Stock Option (Right to Buy) Buy Bollard Catherine 22 000
Jun 03, 2024 Stock Option (Right to Buy) Buy Simon Mark 22 000
Jun 03, 2024 Stock Option (Right to Buy) Buy Henriques Richard C Jr 22 000
Jun 03, 2024 Stock Option (Right to Buy) Buy Brun Scott C. 22 000
Jun 03, 2024 Stock Option (Right to Buy) Buy Tomasello Shawn 22 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Gerard Michael 100 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Chang David J. 130 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Nichtberger Steven 353 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Marda Anup 130 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Das Arun 100 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Binder Gwendolyn 130 000
Jan 19, 2024 Stock Option (Right to Buy) Sell Binder Gwendolyn 11 000
Jan 19, 2024 Common Stock Buy Binder Gwendolyn 11 000
Jan 19, 2024 Common Stock Sell Binder Gwendolyn 10 300
Jan 19, 2024 Common Stock Sell Binder Gwendolyn 700
Dec 19, 2023 Stock Option (Right to Buy) Sell Binder Gwendolyn 11 000
Dec 19, 2023 Common Stock Buy Binder Gwendolyn 11 000
Dec 19, 2023 Common Stock Sell Binder Gwendolyn 7 868
Dec 19, 2023 Common Stock Sell Binder Gwendolyn 3 132
Nov 20, 2023 Stock Option (Right to Buy) Sell Binder Gwendolyn 11 000
Nov 20, 2023 Common Stock Buy Binder Gwendolyn 11 000
Nov 20, 2023 Common Stock Sell Binder Gwendolyn 3 542
Nov 20, 2023 Common Stock Sell Binder Gwendolyn 7 458
Oct 19, 2023 Stock Option (Right to Buy) Sell Binder Gwendolyn 11 000
Oct 19, 2023 Common Stock Buy Binder Gwendolyn 11 000
Click to get the best stock tips daily for free!

About Cabaletta Bio, Inc.

Cabaletta Bio. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,... CABA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT